

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 3, 2005

PDI, INC.

(Exact name of Registrant as specified in its charter)

DELAWARE	0-24249	22-2919486
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Saddle River Executive Centre
1 Route 17 South,
Saddle River, NJ 07458
(Address of principal executive office)

(201) 258-8450

Registrant's telephone number, including area code:

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective August 3, 2005, the Board of Directors of PDI, Inc. (the "Company") expanded the size of the Company's Board of Directors to 10 directors and appointed Jack E. Stover as a Class III Director. Mr. Stover was appointed to the Audit Committee of the Company's Board of Directors. A copy of the press release issued by the Company regarding Mr. Stover's appointment is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release of PDI, Inc. dated August 9, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDI, INC.

By: /s/ Charles T. Saldarini

Charles T. Saldarini, Vice Chairman
and Chief Executive Officer

Date: August 9, 2005

EXHIBIT INDEX

Exhibit No.	Description
-----	-----
99.1	Press Release of PDI, Inc. dated August 9, 2005

PDI, INC. APPOINTS JACK E. STOVER TO THE BOARD OF DIRECTORS

SADDLE RIVER, N.J., Aug. 9 /PRNewswire-FirstCall/ -- PDI, Inc. (Nasdaq: PDII) a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries, is pleased to announce that Jack E. Stover has been appointed to its Board of Directors and will serve on its Audit Committee.

Mr. Stover is Chief Executive Officer and President of Antares Pharma. He joined Antares Pharma in July 2004 as President and Chief Operating Officer (COO), and in August 2004 he was named Chief Executive Officer and President. Mr. Stover was previously Executive Vice President and CFO of Sicom, Inc., a public injectable pharmaceutical company, which was acquired by Teva Pharmaceutical Industries. Prior to that, Mr. Stover was Executive Vice President for a proprietary women's drug company, Gynetics, Inc., and before Gynetics, he was Senior Vice President of B. Braun Medical, Inc., a private global medical device and product company. For more than five years, Mr. Stover was a partner with PricewaterhouseCoopers, working in their bioscience industry division in New Jersey.

Mr. Stover received his BS in Accounting from Lehigh University.

Charles T. Saldarini, PDI's Vice Chairman and CEO, said, "Jack brings the expertise the Company needs on the Audit Committee, as well as an in-depth understanding of the issues facing emerging and specialty pharmaceutical companies. Jack's knowledge and experience will help us as we increase our emphasis on this important customer segment. I am very pleased with his decision to join our Board and look forward to working closely with him."

About PDI

PDI, Inc. (Nasdaq: PDII) is a diversified sales and marketing services provider to the biopharmaceutical and medical devices and diagnostics industries. PDI's comprehensive set of sales and marketing solutions is designed to increase its clients' strategic flexibility and enhance their efficiency and profitability. Headquartered in Saddle River, NJ, PDI also has offices in Pennsylvania and Illinois.

PDI's sales and marketing services include dedicated contract sales, Select Access(TM), our targeted sales solution that leverages an existing infrastructure, clinical sales teams; marketing research and consulting; and medical education and communications. The company's experience extends across multiple therapeutic categories and includes office and hospital-based initiatives.

PDI's commitment is to deliver innovative solutions, unparalleled execution and superior results for its clients. Through strategic partnership and client-driven innovation, PDI maintains some of the longest standing sales and marketing relationships in the industry. Recognized as an industry pioneer, PDI remains committed to continued innovation.

For more information, visit the Company's website at <http://www.pdi-inc.com>.

SOURCE PDI, Inc.

-0- 08/09/2005

/CONTACT: Stephen P. Cotugno, Executive Vice President-Corporate Development of PDI, Inc., +1-201-574-8617/

/Web site: <http://www.pdi-inc.com/>

(PDII)